The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / New Paradigm Investing

URL:  https://boards.fool.com/24214983.aspx

Subject:  Re: PDLI - Tinker and All Date:  6/11/2006  3:04 PM
Author:  dumaflotchie Number:  27143 of 116519

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BC77E7D3D%2DEC70%2D4CA0%2DB118%2D88D6E940B549%7D&source=blq%2Fyhoo&dist=yhoo&siteid=yhoo

PDL said that it now sees 2006 earnings of between 7 cents and 19 cents a share, excluding items, on revenue of $400 million to $430 million. It added that it now anticipates license and related revenue coming in between $55 million and $65 million, reflecting a slight drop in reimbursement payments from partners Roche and Biogen Idec Inc

OK....that is quite a range of earnings estimates from 7 to 19 cents.


http://biz.yahoo.com/ap/060503/pdl_biopharma_mover.html?.v=1

As a result, investment firm First Albany downgraded PDL to a "Buy" from a "Strong Buy," and cut its price target to $30 from $40. First Albany lowered its earnings per share estimate, excluding items, to break-even from 2 cents for the year.........................

Citigroup, which rates the company at "Hold," lowered its earnings per share estimate to 11 cents from 42 cents for the year, and Prudential, which rates PDL at "Overweight," cut its estimate to 14 cents from 45 cents per share.


Talk about all over the map of etimates........company says what they say, analysts are all over the place. Interesting set up...


Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us